With a market cap of $161.3 billion, New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. Known ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

With a robust clinical pipeline and growing oncology footprint, Pfizer's discount to peers looks increasingly disconnected ...

Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...

Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to demonstrate concrete ...

Taking full advantage of the stock market and investing with confidence ... the most attractive and most discounted stocks. New York-based Pfizer markets a wide range of drugs and vaccines.

Revenue came in at $17.7 billion, an increase of 31% year over year, which is beyond excellent for a pharmaceutical giant.

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported third-quarter earnings of $4.47 billion. The New York-based company said it had net income of 78 cents per share.

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer (NYSE:PFE – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, October ...